Clear Creek Financial Management LLC Invests $352,000 in TransMedics Group, Inc. (NASDAQ:TMDX)

Clear Creek Financial Management LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 5,638 shares of the company’s stock, valued at approximately $352,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in shares of TransMedics Group by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after buying an additional 10,106 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in TransMedics Group by 5.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares during the period. Vaughan Nelson Investment Management L.P. boosted its position in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the period. Finally, Principal Financial Group Inc. increased its holdings in shares of TransMedics Group by 260.1% in the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after purchasing an additional 146,115 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

TMDX has been the topic of a number of research analyst reports. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Robert W. Baird decreased their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. TD Cowen dropped their price objective on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Canaccord Genuity Group decreased their target price on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $122.70.

Insider Activity at TransMedics Group

In other news, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward M. Basile sold 6,750 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now directly owns 732 shares in the company, valued at $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $67.55 on Monday. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 71.86 and a beta of 2.12. The company’s 50-day moving average is $67.28 and its two-hundred day moving average is $111.99. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.